Skip to content
Cyclodextrin News

Cyclodextrin News

A forum for researchers, students and applicants in the field of cyclodextrin technology

  • Home
  • Pharma applications
  • Non-pharma applications
  • CD derivatives
  • Events
  • E-ducation

Tag: oral

November 14, 2022 Drug delivery / Pharma applications

Per-thiolated cyclodextrins: Nanosized drug carriers providing a prolonged gastrointestinal residence time

Oral delivery is one of the most advantageous routes for drug administration, but due to the short gastrointestinal (GI) residence

Continue reading

November 23, 2020 CD derivatives / Drug delivery / Pharma applications

Inclusion complex based on N-acetyl-L-cysteine and arginine modified hydroxypropyl-β-cyclodextrin for oral insulin delivery

Insulin is the most effective drug in the treatment of diabetes mellitus. At present, subcutaneous injection is still the common

Continue reading

September 26, 2018 Drug delivery / Pharma applications

Bitter taste? Masked!

Although there are several commercial examples for the uses of cyclodextrins as taste-masking agents (Nicorette, Ulgut, Zyrtec, etc), their use

Continue reading

September 24, 2018 Drug delivery / Pharma applications

Cyclodextrins in oral formulations – has the time of supergenerics come?

Development of generic formulations with cyclodextrins for oral delivery has been neglected for several decades, since the CD-enabled formulations often

Continue reading

August 1, 2018 CD as API / Pharma applications

First cannabidiol product approved by FDA as medication

Cannabis has been used for medicinal purposes for thousands of years. Its active compounds produce pharmacological effects throughout the body,

Continue reading

Recent Posts

  • Special Issue “Cyclodextrin-Functionalized Materials for Drug Delivery, Pharmaceutical and Medical Applications”
  • Cyclodextrin-Based Oral Solution of Ursodeoxycholic Acid Using a Ready-to-Use Vehicle
  • Cyclodextrin-based electrochemical sensors for PFAS detection
  • FDA: Inclusion complex of a GRAS guest and a GRAS host is also GRAS
  • HPBCD for the treatment of irreversible white matter injury

Tags

alpha-CD Alzheimer disease atherosclerosis Cancer therapy Captisol Cholesterol Clinical trial conference Covid-19 cyclodextrin polymer Dexolve drug delivery drug delivery systems electrospinning FDA Food gamma-CD Gilead HPBCD hydrogel methyl BCD Nanoparticles Niemann Pick Disease RAMEB remdesivir review SBECD Special issue Synthesis

Follow Us

  • LinkedIn
  • X
  • Facebook

Categories

  • Agriculture (27)
  • Analysis (72)
  • CD as API (350)
  • CD derivatives (422)
  • Cosmetics and toilettry (52)
  • Diagnosis (13)
  • Drug delivery (803)
  • E-ducation (63)
  • Environmental (140)
  • Events (236)
  • Food (229)
  • Gene delivery (22)
  • Household products (5)
  • Household products (1)
  • In Hungarian (4)
  • Life sciences (44)
  • Non-pharma applications (408)
  • Other industrial use (110)
  • Pharma applications (1,200)
  • Supramolecular systems (44)
  • Uncategorized (161)

Top Posts

  • Special Issue "Cyclodextrin-Functionalized Materials for Drug Delivery, Pharmaceutical and Medical Applications"
  • Cyclodextrin-Based Oral Solution of Ursodeoxycholic Acid Using a Ready-to-Use Vehicle
  • Cyclarity Unveils First-Ever Clinical Data Demonstrating Excretion of Oxidized Cholesterol, at American Heart Association Vascular Discovery Scientific Sessions
  • 4th International Biotechnology Congress 2020
  • Cholesteryl Cyclodextrin for Enhanced Delivery of Doxorubicin and 5-Fluorouracil
  • Call for Book Chapters: Cyclodextrin Systems for Green Hydrogen Production
  • Call for Chapters: Cyclodextrins in Nutraceuticals 
  • FDA: Inclusion complex of a GRAS guest and a GRAS host is also GRAS
  • Early peek at data on Gilead coronavirus drug suggests patients are responding to treatment
  • Nystatin:β-cyclodextrin inclusion complexes - revisited

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 4,475 other subscribers

Loading Comments...